If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Mark Shackleton is Director of Oncology at Alfred Health and Professor of Oncology in the Department of Medicine, Monash Univerisity.

Department of Medicine (Alfred) Research Laboratories - Shackleton Group

After training in medical oncology and at the Ludwig Institute in Melbourne, Prof Shackleton undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA, with resultant publications in Nature, Cell, Cancer Cell and the New England Journal of Medicine. He was awarded the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, a 2011 Pfizer Australia Fellowship, and in 2012 received the Australian Science Minister’s Prize for Life Scientist of the Year

Most recently a Medical Oncologist and Head of the Cancer Development and Treatment Laboratory at the Peter MacCallum Cancer Centre, Prof Shackleton’s main clinical interests are centred on patients diagnosed with skin cancer, including melanoma. His research interests include cancer biology, developmental biology, oncogenic signaling pathways and clinical trials.

Keywords

  • Melanoma
  • Cancer Therapeutics

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2021

Research Output 2003 2019

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

Pires da Silva, I., Glitza, I. C., Haydu, L. E., Johnpulle, R., Banks, P. D., Grass, G. D., Goldinger, S. M. A., Smith, J. L., Everett, A. S., Koelblinger, P., Roberts-Thomson, R., Millward, M., Atkinson, V. G., Guminski, A., Kapoor, R., Conry, R. M., Carlino, M. S., Wang, W., Shackleton, M. J., Eroglu, Z. & 5 othersLo, S., Hong, A. M., Long, G. V., Johnson, D. B. & Menzies, A. M., 1 Jul 2019, In : Pigment Cell and Melanoma Research. 32, p. 553-563 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Personalised surveillance after treatment for high-risk cancer

Guo, C., Lewin, J. & Shackleton, M., 1 Jan 2019, In : Oncotarget. 10, 7, p. 694-695 2 p.

Research output: Contribution to journalEditorialOtherpeer-review

Open Access

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., Hatzimihalis, A., Henderson, M. A., Shackleton, M., Haydon, A., Mar, V., Gyorki, D. E., Oudit, D., Dawson, M. A., Hicks, R. J., Lorigan, P. & 4 othersMcArthur, G. A., Marais, R., Wong, S. Q. & Dawson, S. J., 1 May 2019, In : Annals of Oncology. 30, 5, p. 804-814 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma

Zhang, X., Tang, J. Z., Vergara, I. A., Zhang, Y., Szeto, P., Yang, L., Mintoff, C., Colebatch, A., McIntosh, L., Mitchell, K. A., Shaw, E., Rizos, H., Long, G. V., Hayward, N., McArthur, G. A., Papenfuss, A. T., Harvey, K. F. & Shackleton, M., 1 Jul 2019, In : Molecular Cancer Research. 17, 7, p. 1435-1449 15 p.

Research output: Contribution to journalArticleResearchpeer-review

Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

Mitchell, E. L., Lau, P. K. H., Khoo, C., Liew, D., Leung, J., Liu, B., Rischin, A., Frauman, A. G., Kee, D., Smith, K., Brady, B., Rischin, D., Gibson, A., Mileshkin, L., Klein, O., Weickhardt, A., Arulananda, S., Shackleton, M., McArthur, G., Östör, A. & 7 othersCebon, J., Solomon, B., Buchanan, R. RC., Wicks, I. P., Lo, S., Hicks, R. J. & Sandhu, S., 1 Dec 2018, In : European Journal of Cancer. 105, p. 88-102 15 p.

Research output: Contribution to journalArticleResearchpeer-review